8 results about "Ventricular function" patented technology

The invention features methods for the treatment of a cardiovascular disease using a polypeptide containing an extracellular ActRII variant, such as an ActRIIA variant, ActRIIB variant, or ActRII chimera. The polypeptide may include an extracellular ActRII variant fused to an Fc domain monomer. Treatment of a cardiovascular disease with a polypeptide described herein may reduce fibrosis, reduce inflammation, reduce cardiac remodeling, improve cardiac function, improve ventricular function, or slow or inhibit disease progression, which may reduce or delay the need for coronary revascularization, heart valve repair or replacement, implantation of a cardioverter-defibrillator, cardiac resynchronization therapy, a ventricular assist device, or a heart transplant.

The application discloses a method, system, device, medium and product for evaluating right ventricular function, and relates to the technical field of medical image processing and ultrasonic diagnosis. The method comprises the following steps: acquiring a sequence of multiple two-dimensional ultrasonic images of a right ventricle of a heart and spatial pose information of the sequence, and generating point cloud data; identifying an end-diastolic frame, an end-systolic frame and an anatomical structure point, and acquiring sparse point cloud data of the anatomical structure point; constructing a three-dimensional grid model of the end-diastolic frame and the end-systolic frame; determining multiple tracking points of a tricuspid annulus and acquiring a three-dimensional coordinate trajectory; calculating longitudinal displacement, area change rate and peak time dispersion based on the trajectory, and completing function evaluation. The application overcomes the limitations of angle dependence and point substitution of traditional TAPSE technology, realizes comprehensive evaluation of right ventricular function from three dimensions of longitudinal displacement, area change rate and systolic synchrony, and improves the accuracy and clinical value of evaluation.

The application provides use of a trisaccharide compound with a core structure of GlcN(1→4)IdoA(1→4)GlcNS in preparation of a drug for treating or preventing pulmonary arterial hypertension, which can effectively improve right ventricular hypertrophy, right ventricular function damage and hemodynamic parameters of an animal model of the pulmonary arterial hypertension, delay or improve excessive proliferation of arterial endothelial cells and smooth muscle cells in the pulmonary arterial hypertension, treat vascular remodeling and vascular muscularization of a pulmonary arterial hypertension patient, and has a good protective effect on a heart in the pulmonary arterial hypertension.

The utility model belongs to the technical field of pulmonary vessel guiding catheters, and particularly relates to a pulmonary vessel guiding catheter which can be used for right heart function examination. The technology comprises a guiding catheter, and a floating catheter is arranged in the guiding catheter in a penetrating mode. According to the technical scheme, the functions of an existing right heart floating catheter and an existing pulmonary vessel guiding catheter are organically combined, and the function effects of the original right heart floating catheter and the original pulmonary vessel guiding catheter are achieved through one set of technical scheme. Specifically, a guiding catheter in the prior art is adopted, and physical characteristics such as proper flexibility and strength are utilized to adapt to various bends and steers in a blood vessel; a floating catheter in the prior art is adopted to realize pulmonary vessel intervention operation; the floating catheter is arranged in the guiding catheter, so that the guiding catheter can be used for right heart function examination and pulmonary vessel intervention operation, and clinical diversified requirements are met.

The invention discloses a method, a system, equipment, a medium and a product for evaluating a right ventricular function, and relates to the technical field of medical image processing and ultrasonic diagnosis. The method comprises the following steps: acquiring a multi-frame two-dimensional ultrasonic image sequence of a right ventricle of a heart and spatial pose information of the multi-frame two-dimensional ultrasonic image sequence, and generating point cloud data; identifying the last diastole frame, the last systole frame and the anatomical structure point, and obtaining sparse point cloud data of the anatomical structure point; constructing a three-dimensional grid model of the last diastole frame and the last systole frame; determining a plurality of tracking points of the tricuspid valve ring and acquiring a three-dimensional coordinate trajectory; and calculating the longitudinal displacement, the area change rate and the peak arrival time dispersion based on the trajectory to complete the function evaluation. According to the method, the limitation that a traditional TAPSE technology depends on a point instead of a surface is overcome, comprehensive evaluation of the right ventricular function from the three dimensions of longitudinal displacement, the area change rate and contraction synchronism is achieved, and the accuracy and clinical value of evaluation are improved.

Disclosed herein, in some aspects, are systems and methods for treating hypertrophic cardiomyopathy (HCM) in a subject. In some embodiments, the systems and methods described herein comprise monitoring a cardiac performance and optionally detecting an abnormality of said cardiac performance, in some cases after an initial HCM treatment is administered. In some cases, the initial HCM treatment includes administration of a myosin inhibitor, and / or septal myectomy. In some embodiments, said cardiac performance correlates with a right ventricular function and / or a pulmonary arterial pressure. In some embodiments, systems and methods described herein comprise identifying a therapy for a subject so as to help reduce the risk of de-performance teriorating a cardiac performance. In some cases, identifying the therapy includes predicting an effectiveness of a therapy with respect to a cardiac performance. In some embodiments, a recommendation is provided for adjusting a therapy based on an observed effect on a cardiac performance.

This invention belongs to the field of traditional Chinese medicine, specifically relating to a traditional Chinese medicine composition for preventing and treating cardiotoxicity induced by doxorubicin and its application; the traditional Chinese medicine composition for preventing and treating cardiotoxicity induced by doxorubicin is composed of ginseng and salvia miltiorrhiza; this invention finds that the traditional Chinese medicine composition can promote the survival rate of doxorubicin-induced cardiomyocyte H9c2, reduce doxorubicin-induced apoptosis of cardiomyocyte H9c2, reduce doxorubicin-induced oxidative stress damage and cardiac damage, improve left ventricular function, and improve doxorubicin-induced cardiotoxicity, which is of great significance for the prevention and treatment of azithromycin-induced cardiotoxicity.

Various methods and compositions for treating single ventricle heart disease (SVHD) patients, including patients who have undergone Fontan surgery and who have Fontan circulation (Fontan patient), to improve exercise performance, single ventricular performance, cardiac output and myocardial performance index (MPI) in the SVHD patients, including the Fontan patients, using udenafil compositions.In one exemplary embodiment, the methods of the present invention include administering an effective amount of udenafil or a pharmaceutically acceptable salt thereof to a SVHD patient, including a Fontan, to improve the ventricular performance of the SVHD patient's, including the Fontan patient's, single functioning ventricle.In another exemplary embodiment, the methods of the present invention include administering an effective amount of udenafil or a pharmaceutically acceptable salt thereof to a SVHD patient, including a Fontan patient, to improve the SVHD patient's, including the Fontan patient's, MPI.In still another exemplary embodiment, the methods of the present invention include administering an effective amount of udenafil or a pharmaceutically acceptable salt thereof to a SVHD patient, including a Fontan patient, to improve the SVHD patient's, including the Fontan patient's, cardiac output.In yet another exemplary embodiment, the methods of the present invention include administering an effective amount of udenafil or a pharmaceutically acceptable salt thereof to a SVHD patient, including a Fontan patient, who is about 6 years of age or older, to improve at least one or more or all of the following in the SVHD patient, including the Fontan patient: (a) ventricular performance of the SVHD patient's, including a Fontan patient's, single functioning ventricle as measured by MPI; (b) exercise capacity as measured by oxygen consumption at anaerobic threshold (VAT); (c) exercise capacity as measured by oxygen consumption at maximal effort or max VO2; (d) work rate at VAT; (e) VE / VCO2 at VAT; diastolic blood pressure at rest; and (g) oxygen saturation (%) at rest.